Annalisa Chiappella, Beatrice Casadei, Patrizia Chiusolo, Alice Di Rocco, Silva Ljevar, Martina Magni, Piera Angelillo, Anna Maria Barbui, Ilaria Cutini, Anna Dodero, Francesca Bonifazi, Maria Chiara Tisi, Stefania Bramanti, Maurizio Musso, Mirko Farina, Massimo Martino, Mattia Novo, Giovanni Grillo, Francesca Patriarca, Giulia Zacchi, Mauro Krampera, Martina Pennisi, Eugenio Galli, Maurizio Martelli, Andrés J M Ferreri, Silvia Ferrari, Riccardo Saccardi, Anisa Bermema, Anna Guidetti, Rosalba Miceli, Pier Luigi Zinzani, Paolo Corradini
Axicabtagene ciloleucel showed efficacy for relapsed/refractory large B-cell lymphomas (LBCL), including primary mediastinal B-cell lymphomas (PMBCL); however, only few PMBCLs were reported. Aim was to evaluate efficacy and safety of axicabtagene ciloleucel in patients with PMBCL compared to those with other LBCL, enrolled in the Italian prospective observational CART-SIE study. PMBCLs (n = 70) were younger, with higher percentage of bulky and refractory disease, compared to other LBCLs (n = 190)...
March 8, 2024: Leukemia